Skip to main content Skip to main navigation menu Skip to site footer

Comparing the effect of Angiotensin-Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers in heart failure patients with type 2 diabetes mellitus: a systematic review

  • Ratih Puspita Febrinasari ,
  • Bambang Irawan Martohusodo ,
  • Erna Kristin ,
  • Ricvan Dana Nindrea ,
  • Iwan Dwiprahasto ,


Abstract

Abstract:

Introduction: Heart failure is a prevalent world wide. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are widely prescribed. The aim of this study was to determine the effect of the two drugs in heart failure patients with type 2 diabetes mellitus.

Methods: This meta-analysis was performed on research articles on the drugs of heart failure patients in PubMed, ProQuest and EBSCO database published between 2008-2018. Pooled odds ratio (OR) are calculated using fixed and random effects models. Data were processed using Review Manager 5.3 (RevMan 5.3).

Results: From total 209 articles, 10 studies met the criteria for systematic review. Meta-analysis result showed that there were no difference effect of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in heart failure patients with type 2 diabetes mellitus (RR = 1.73 [95% CI 0.88-3.40], p=0.11). Heterogeneity test for studies (Pheterogeneity = <0.00001) showed variation of heterogeneous research. There is no publication bias on this study Egger’s test (p = 0.334) and Begg’s test (p = 0.180).

Conclusion: This analysis confirmed there were no difference effect of angiotensin-converting enzyme inhibitors (ACEi) versus angiotensin receptor blockers (ARBs) in heart failure patients with type 2 diabetes mellitus
Keywords: heart failure angiotensin-converting enzyme inhibitors angiotensin receptor blockers type 2 diabetes mellitus

References

  1. Roger VL. The heart failure epidemic. Int J Environ Res Public Health. 2010;7(4):1807–30.
  2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart Disease and Stroke Statistics—2012 Update. Circulation. 2011;125(1):2–220.
  3. NICE. Chronic heart failure in adults: management. NiceOrgUk/Guidance/Cg108. 2010;(1–47).
  4. MacDonald MR, Petrie MC, Varyani F, Östergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure - An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377–85.
  5. Bouthoorn S, Gohar A, Valstar G, den Ruijter HM, Reitsma JB, Hoes AW, et al. Prevalence of left ventricular systolic dysfunction and heart failure with reduced ejection fraction in men and women with type 2 diabetes mellitus: A systematic review and meta-analysis. Cardiovasc Diabetol. 2018;17(1):1–14.
  6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200m.
  7. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡. Eur J Heart Fail. 2008;10(10):933–89.
  8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):1495–539.
  9. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet. 2000;355(9215):1575–81.
  10. Heran B, Vm M, Bassett K, Rs T, Jm W. Angiotensin receptor blockers for heart failure ( Review ). 2012;(4).
  11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.
  12. Ertek S, Cicero AF, Cesur M, Akcil M, Kayhan TA, Avcioglu U, et al. The severity of coronary atherosclerosis in diabetic and non-diabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography. Acta Diabetol. 2011;48(1):21–7.
  13. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126–35.
  14. Imai E, Chan JCN, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86.
  15. Yamashita K, Kondo T, Muramatsu T, Matsushita K, Nagahiro T, Maeda K, et al. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. Am J Cardiol. 2013;112(11):1750–6.
  16. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction: A Report from the I-Preserve Trial (Irbesartan in Heart Failure with Preserved Ejection. Circulation. 2017;135(8):724–35.
  17. Kawai T, Takei I, Shimada A, Hirata T, Tanaka K, Itoh YS, et al. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: A preliminary, observational, open-label study. Clin Drug Investig. 2011;31(4):237–45.
  18. Elliott WJ. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. Yearb Cardiol. 2012;2011:69–71.
  19. Muramatsu T, Mastsu K, Yamashita K, Kondo T, Maeda K, Shintani S. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance NGOYA heart study. 2018;(August).
  20. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: Subgroup analyses from the ontarget (ongoing telmisartan alone and in combination with ramipril global endpoint trial). J Am Coll Cardiol. 2012;59(1):74–83.
  21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
  22. Gorthi J, Hunter CB, Mooss AN, Alla VM, Hilleman DE. Reducing Heart Failure Hospital Readmissions: A Systematic Review of Disease Management Programs. Cardiol Res. 2014;5(5):126–38.
  23. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993–1004.

How to Cite

Febrinasari, R. P., Martohusodo, B. I., Kristin, E., Nindrea, R. D., & Dwiprahasto, I. (2019). Comparing the effect of Angiotensin-Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers in heart failure patients with type 2 diabetes mellitus: a systematic review. Bali Medical Journal, 8(3), 757–761. https://doi.org/10.15562/bmj.v8i3.1534
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
4

Total
1

Share

Search Panel

Ratih Puspita Febrinasari
Google Scholar
Pubmed
BMJ Journal

Bambang Irawan Martohusodo
Google Scholar
Pubmed
BMJ Journal

Erna Kristin
Google Scholar
Pubmed
BMJ Journal

Ricvan Dana Nindrea
Google Scholar
Pubmed
BMJ Journal

Iwan Dwiprahasto
Google Scholar
Pubmed
BMJ Journal